These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16631354)

  • 21. Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.
    Sun F; Stock EM; Copeland LA; Zeber JE; Ahmedani BK; Morissette SB
    Am J Health Syst Pharm; 2014 May; 71(9):728-38. PubMed ID: 24733136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and correlates of antipsychotic polypharmacy in Hong Kong.
    Lung SLM; Lee HME; Chen YHE; Chan KWS; Chang WC; Hui LMC
    Asian J Psychiatr; 2018 Mar; 33():113-120. PubMed ID: 29574303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study.
    Boskailo E; Malkoc A; McCurry DB; Venter J; Drachman D; Ramos GM
    Acta Med Acad; 2017 Nov; 46(2):133-144. PubMed ID: 29338277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic polypharmacy in schizophrenia: benefits and risks.
    Barnes TR; Paton C
    CNS Drugs; 2011 May; 25(5):383-99. PubMed ID: 21476610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital.
    Stone-Brown K; Naji M; Francioni A; Myers K; Samarendra H; Mushtaq-Chaudhry H; Heslop S; Sengupta S; Ross CC; Larkin F; Das M
    CNS Spectr; 2016 Feb; 21(1):60-9. PubMed ID: 26726766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
    Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
    J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polypharmacy with second-generation antipsychotics: a review of evidence.
    Pandurangi AK; Dalkilic A
    J Psychiatr Pract; 2008 Nov; 14(6):345-67. PubMed ID: 19057237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.
    Li Q; Xiang YT; Su YA; Shu L; Yu X; Chiu HF; Correll CU; Ungvari GS; Lai KY; Ma C; Wang GH; Bai PS; Li T; Sun LZ; Shi JG; Chen XS; Mei QY; Li KQ; Si TM
    Aust N Z J Psychiatry; 2015 Feb; 49(2):129-36. PubMed ID: 24923760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
    Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
    Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality.
    Kadra G; Stewart R; Shetty H; MacCabe JH; Chang CK; Taylor D; Hayes RD
    Acta Psychiatr Scand; 2018 Aug; 138(2):123-132. PubMed ID: 29845597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of switching from antipsychotic polypharmacy to monotherapy.
    Essock SM; Schooler NR; Stroup TS; McEvoy JP; Rojas I; Jackson C; Covell NH;
    Am J Psychiatry; 2011 Jul; 168(7):702-8. PubMed ID: 21536693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy.
    Iversen TSJ; Steen NE; Dieset I; Hope S; Mørch R; Gardsjord ES; Jørgensen KN; Melle I; Andreassen OA; Molden E; Jönsson EG
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():263-271. PubMed ID: 29122637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia: An Egyptian Study.
    Aly El-Gabry DM; Abdel Aziz K; Okasha T; Azzam H; Okasha A
    J Clin Psychopharmacol; 2018 Feb; 38(1):27-33. PubMed ID: 29210867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
    Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E
    Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used?
    Constantine RJ; Andel R; McPherson M; Tandon R
    Psychiatry Res; 2018 May; 263():238-244. PubMed ID: 29195836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
    Velligan DI; Carroll C; Lage MJ; Fairman K
    Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.
    Fisher MD; Reilly K; Isenberg K; Villa KF
    BMC Psychiatry; 2014 Nov; 14():341. PubMed ID: 25433495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comments on "The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A pragmatic randomized open-label trial (SwAP trial)".
    Shankar A; Tripathi A
    Schizophr Res; 2024 Feb; 264():402-403. PubMed ID: 38237362
    [No Abstract]   [Full Text] [Related]  

  • 39. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.
    Leslie DL; Rosenheck RA
    J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
    Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.